Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$1MCash on Hand
1.2mo Cash Runway
Follow SXTP by emailGet an email when SXTP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SXTP, unsubscribe in one click. Privacy
📣 What SXTP Says Is Next
in January 2027 · “Primary and secondary endpoint results are expected in January 2027”
Company press release, Oct 6, 2026 · SEC filing
first quarter of 2028 · “The Company intends to submit an application for a Commissioner’s National Priority Review Voucher if the outcome of any interim and/or final analysis of the Company’s randomized, placebo-controlled trial of tafenoquine in patients hospitalized with severe babesiosis supports moving forward with a supplementary New Drug Application (sNDA) submission to the FDA before the end of the first quarter of 2028.”
Company press release, Jul 9, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 6, 2026 ·
Financing Entered inducement letters with warrant holders to exercise 584,492 existing warrants at $0.90 per share, for expected gross proceeds of $526,042.80, in exchange for new unregistered warrants covering 1,168,984 shares. New warrants require Nasdaq stockholder approval before exercise. Form 8-K · SEC filing
Oct 27, 2026 ·
Clinical trial Reports clinical improvement and negative PCR results in all five completed expanded access babesiosis patients, with four of five (80%) nonreactive on a highly sensitive post-treatment NAT test. Form 8-K · SEC filing · Press release
Oct 23, 2026 ·
Furnished an updated investor presentation dated October 23, 2026, for use in investor meetings, covering its tafenoquine program for babesiosis. The presentation references a potential sNDA in 2027 and a request for national-priority review. Form 8-K · SEC filing · Press release
Oct 6, 2026 ·
Clinical trial Updated its investor presentation for October 6, 2026 and issued a press release updating its January 2027 hospitalized babesiosis data readout. Hospital study has 30 patients enrolled as of 10/1/2026, with follow-up through early January 2027. Form 8-K · SEC filing · Press release
Sep 14, 2026 ·
Regulatory Submitted a Statement of Interest on September 12, 2026 requesting a Commissioner's National Priority Voucher for an efficacy supplement to NDA 210607 for ARAKODA (tafenoquine) to treat babesiosis, a condition with no FDA-approved therapy. Form 8-K · SEC filing
Sep 8, 2026 ·
60 Degrees Pharmaceuticals updated its investor presentation for use in investor meetings, furnished as Exhibit 99.1. The presentation cites Q2 2026 net product revenue of $208k, up 106% year over year, and about $1.0M in cash as of June 30, 2026, with runway into early October 2026. Form 8-K · SEC filing · Press release
Aug 14, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Feb 2027 · Phase 2 · Recruiting · B-FREE Chronic Babesiosis Study Registry primary completion date, not a results date
Mar 2027 · Phase 2 · Recruiting · Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
SXTP holds $1M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.5M/quarter from operations,
an estimated runway of 1.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:70 · High
Cash runway 0 months +40
ATM program on file since Mar 2026 +15
Shelf registration (S-3, Jul 2024) +10
Going-concern doubt in the latest 10-Q +15These conditions, among others, raise substantial doubt about the ability of the Company to continue as a going concern for one year from the date these consolidated condensed financial statements are issued.10-Q, Nov 2026
Raised after last reported balance sheet (Nov 2026) -10
Share count 4,484,622 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full SXTP picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SXTP and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.